CCS
TWST icon

Crosspoint Capital Strategies’s Twist Bioscience TWST Stock Holding History

Crosspoint Capital Strategies’s Portfolio TWST Stock Details TWST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,300
Closed -$64K – 30
2022
Q1 		$64K Buy
+1,300
New +$72K 0.18% 12

Other funds holding TWST

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Crosspoint Capital Strategies's TWST Position: Q2 2022 in Review

Crosspoint Capital Strategies sold out of Twist Bioscience (TWST) in Q2 2022, closing a stake of 1,300 shares — an estimated $64K sold.

Crosspoint Capital Strategies first reported a position in TWST in Q1 2022 and held it in 1 quarter. The position peaked at $64K in Q1 2022. 204 funds tracked by Wall St. Rank hold TWST as of Q2 2022.

  • Crosspoint Capital Strategies reported no remaining Twist Bioscience position as of Q2 2022 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 1,300 Twist Bioscience shares in Q2 2022, an estimated $64K.
  • Crosspoint Capital Strategies first reported a position in Twist Bioscience in Q1 2022 and held it in 1 quarter.
  • Crosspoint Capital Strategies's Twist Bioscience position peaked at $64K in Q1 2022.
  • 204 funds tracked by Wall St. Rank held Twist Bioscience as of Q2 2022.

Based on Crosspoint Capital Strategies's 13F filing for Q2 2022, filed 12 Aug 2022.